Which condition is an indication for fibrinolytic therapy in ACS management?

STEMI

In fibrinolytic therapy for ACS, the key indication is an acute ST-elevation myocardial infarction. That ECG pattern means a complete occlusion of a coronary artery with ongoing transmural ischemia, where dissolving the clot can promptly restore blood flow and limit heart muscle damage. Fibrinolytics are most beneficial when given as early as possible after symptoms begin, ideally within the first few hours.

If a patient can have primary PCI quickly, that approach is usually preferred because it more reliably reopens the artery and carries a lower bleeding risk compared with fibrinolysis. For non‑ST elevation ACS—NSTEMI and unstable angina—the problem is not a persistent ST‑segment elevation from a complete occlusion, so fibrinolysis does not provide a benefit and is avoided to prevent unnecessary bleeding. Variant angina is due to coronary vasospasm rather than a thrombotic occlusion, so vasodilator therapy is the approach and fibrinolysis isn’t indicated.

NSTEMI

Unstable Angina

Variant Angina

Want more questions?

All options are one-time payments.

$25.99

30 day pass for new members

All the basics to get you started

  • Ad-free experience
  • View your previous attempt history
  • Mobile app access
  • In-depth explanations
  • 30 day premium pass access
$59.99$171.99 usd

6 month DELUXE pass (most popular)

Full access FOR 6 MONTHS! & the ultimate digital PDF study guide (BONUS)

  • $171.99 usd value for $59.99! You save $106!
  • Ad-free experience
  • View your previous attempt history
  • Mobile app access
  • In-depth explanations
  • 6 months of full access
  • Ultimate digital PDF study guide included
  • Priority support
$15.99 $24.99

Ultimate digital PDF study guide

For those that prefer a more traditional form of learning

  • Available for instant download
  • Available offline
  • Hundreds of practice multiple choice questions
  • Comprehensive content
  • Detailed explanations
Image Description
Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy